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I. INTRODUCTION 
Cancer is the first or second leading cause for death in many countries (e.g. 
Germany) with almost 10 million deaths versus an incidence of about 18 
million worldwide in the year 2018 [1]. In Germany the number of cancer 
diagnoses has risen from close to 1.5 up to over 1.6 million from 2006 to 
2016 [2], which equates to a rise of over 10% within 10 years, although 
population was constant. Males diagnosed with cancer most often exhibit 
affection of the lung, while female patients most commonly suffer from 
breast cancer. Independent of sex, cancer diagnosis rates are increasing 
with age for most cancer types [1]. Other risk factors for coming down with 
cancer are inter alia alcohol and tobacco use, overweight, missing physical 
activity and inadequate nutrition [3]. These facts and numbers illustrate the 
importance of effective treatment options. 
Tumor cells emerge from normal healthy cells that mutate for diverse 
reasons. Subsequently these alterations can lead to malignant tumor 
development. Responsible for this is the genetic makeup next to a variety 
of external biological, chemical and physical causes and of course the 
aforementioned ageing [3]. 
Once a patient is suffering from cancer, the sooner he is diagnosed the 
better are his future prospects concerning survival, under all circumstances 
and for the plural of cancer types. For this reasons, regular screenings have 
been established for certain cancers and can help to diagnose at an early 
timepoint. To treat tumors effectively an accurate tumor diagnosis is vital to 
initiate treatment. Common established treatment options, including 
surgery, radio- and chemotherapy, have their limitations. Metastasis e.g. 
restricts the potential of surgery and radiation because removing 
respectively erasing the original tumor is not sufficient in these cases. 
Furthermore, tumor cells can become resistant to conventional 
chemotherapeutic agents, which means they negate and disable the mode 
of action of these drugs and therefore their therapeutic potential [4]. 
Considering these problems of common treatment regime, new innovative 
approaches like gene therapy that depend on the reliable transport (e.g. by 
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non-viral vectors) into the target cell [5], are urgently needed. Hence, this 
thesis focuses on the evaluation of sequence-defined polymeric carriers for 
effective and tumor selective delivery of small interfering RNA (siRNA) using 
hyaluronic acid (HA) as a shielding and targeting agent. 
1. Nucleic acid treatment via siRNA 
Genomic analysis enabled the identification of multiple genes that are 
involved in tumor formation and spread [6]. This leads to the conclusion that 
these genes constitute possible targets for cancer therapy [7]. Possible 
candidates are nucleic acids containing drugs that can modify the 
expression of tumor related genes [8]. The group encompasses among 
other things messenger RNA (mRNA) and plasmid DNA (pDNA) [9] that 
lead to an increased gene expression, whereas siRNA (double-stranded) 
and antisense oligonucleotides (single-stranded) achieve the opposite by 
impeding functional mRNA [10, 11]. 
siRNA is a non-coding RNA that interferes directly with gene expression. 
The resulting specific knockdown of target genes predestines it for therapy 
of different diseases (e.g. cancer) [12-15]. Consisting of two strands, each 
comprising 21 to 23 nucleotides, siRNA is cleaved after successful delivery 
into the cytoplasm. The sense strand is disassembled, while the antisense 
strand is incorporated into the RNA induced silencing complex (RISC), 
which facilitates subsequent target mRNA identification followed by RNase 
initiated mRNA cleavage (illustrated in Figure 1). The mRNA inactivation 
therefore inhibits formation of disease-associated proteins [10, 12, 16, 17]. 
How promising this approach can be, demonstrates the drug approval of 
Patisiran (OnpattroTM) in 2018 for the US market [18]. It is a liposomal siRNA 
formulation directed against hereditary transthyretin-mediated amyloidosis 
(hATTR) and the first approved siRNA-based drug. Another promising 
candidate is Givosiran (GivlaariTM), an siRNA-based drug that combats 
acute intermittent porphyria (AIP) by interfering with aminolevulinic acid 
(ALA) synthesis, which plays a role in AIP pathogenesis, was approved in 
November 2019 for medical use [19, 20]. 
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Figure 1: Gene silencing effect of siRNA. After endocytosis and release into the cytosol, 
the two strands of siRNA are separated. While the sense (=passenger) strand is 
dismantled, the antisense (= guide) strand undergoes incorporation into the RISC complex. 
This leads to the identification and subsequent RNase-initiated degradation of the 
corresponding target mRNA and results in a reduction of disease-associated gene 
expression [21]. 
1.1. Hurdles 
Concerning tumor targeting, a recent study states that less than 1% of 
injected nanoparticle formulation ultimately reaches tumor tissue [22]. 
SiRNa delivery in particular is facing hurdles, like insufficient tolerability and 
circulation time [23] that have to be solved for efficient and sustainable 
disease treatment, especially for non-liver diseases. Pharmacokinetic 
characteristics of pure siRNA are inadequate and therefore present half-
lives limited to minutes after systemic application [24, 25]. An optimal 
transport system for instable siRNA is therefore crucial and has to overcome 
manifold obstacles like nuclease-triggered degradation [26] and undesired 
agglomeration with blood components, both negatively affecting time of 
circulation [23]. Additionally reactions of the immune system have to be 
evaded by these carriers [12, 27, 28]. Since a particle size below 10 nm 
induces unwanted renal filtration, introducing carrier systems can help to 
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increase the nanoparticle size to a desired limit of around 200 nm [29]. If the 
created particles are stable enough to reach tumor tissue via bloodstream, 
they can passively extravasate due to tumor vessels being more permeable, 
because of gaps between endothelial cells, compared to healthy tissues 
[30-32]. Besides, a recent study suggests that entering tumor tissue might 
be an active process, e.g. binding to endothelial cells followed by trans-
endothelial delivery [33]. Once the formulated siRNA has accessed tumor 
tissue, the endosomal uptake into tumor cells is possible (illustrated in 
Figure 2). The subsequent endosomal escape that can be affected by 
correctly chosen carriers, finally enables free siRNA to cleave target mRNA 
(illustrated in Figure 1). 
 
Figure 2: Delivery of siRNA into tumor cells. After intravenous injection of siRNA 
polyplexes into tail vein and transport in the blood (red), a fraction of the particles enters 
tumor tissue (yellow). Formulations can pass the cell wall and enter the tumor cell (orange) 
by endocytosis. The formed endosome releases siRNA into the cytosol after pH-triggered 
endosomal escape [21]. 
 
1.2. Carrier systems 
The aforementioned barriers can be bypassed with the usage of carrier 
systems with definite characteristics. 
Basically, one can choose between viral and non-viral vectors, which are 
the two main groups when looking for potent transporters. While viral 
vectors can transfect target cells effectively, what can be explained with 
their viral origin, and mostly replication as well as cytotoxicity pose no threat, 
their major disadvantages are immunogenic reactions and genomic 
mutations [34, 35]. In addition, production of sufficient amounts constitutes 
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an issue [36]. 
An encouraging option besides viral vectors to deliver siRNA, are non-viral 
vectors like cationic polymers and liposomes [37]. In combination with 
anionic nucleic acids like siRNA stable nanoparticles, so-called polyplexes 
[38], can form. An important cationic representative is linear 
polyethylenimine (LPEI) [39], though it has major deficits regarding 
reproduceable and lasting stability [40], immune response and 
biodegradability [41]. 
Therefore, this work evaluates carriers with positive charge that are created 
via solid-phase assisted synthesis. To this day our group developed around 
1400 sequence-defined small peptide-like polymers, so-called oligomers. 
These small polycations dispose over different moieties concerning 
structure and function, like the proton-sponge that induces swelling by an 
osmotic gradient and proximate disruption of the endosome [42, 43], to 
facilitate gene delivery. Their reduced size and positive charge make them 
superior compared to other polymers, especially concerning cell toxicity. 
Exact sequence-defined oligomers were created for the first time in 2006 
[44] and subsequently advanced by members of our work group by 
increasing the number of building blocks [45] respectively further structures 
like a polyethylene glycol chain combined with terminal folic acid as 
targeting ligand [46]. 
In the described polymer 1214 (illustrated in Figure 3), the cationic 
backbone consists of the artificial amino acid succinoyl tetraethylene 
pentaamine (Stp). This polymer building block is positively charged, due to 
its partly protonation status at neutral pH, which enables polyplex formation 
when combined with negatively charged siRNA [47]. 
Additional structures are added for positive influence. Amino acids have 
varying effects: tyrosines and cysteines enhance stability by their 
hydrophobic character respectively by forming disulfide bridges [48, 49], 
while histidines support endosomal escape by their proton sponge effect 
[43] and by increasing the endosomal buffering capacity [50]. Azido-lysines 
were introduced to allow post-functionalization with dibenzocyclooctyne 
(DBCO) click agents e.g. hyaluronic acid (HA) via strain-promoted alkyne-
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azide cycloaddition (SPAAC) [51, 52]. This azide function enables 
introduction of shielding as well as targeting ligands onto the surface after 
polyplex formation by smoothly adding DBCO derivates (illustrated in 
Figure 4). 
Like tyrosine, the fatty acid, oleic acid, has a comparably positive effect on 
polyplex stability, which is important in particular for siRNA delivery [53]. In 
addition, it improves the lysis of the lipid membrane of the endosome during 
the process of endosomal escape [54]. 
The topology of the polymer also impacts the way siRNA can be 
incorporated into the resulting polyplex. To deliver siRNA, T-shaped 
oligomers, that normally consist of two hydrophobic fatty acids bound to the 
positively charged Stp-backbone, demonstrated high aptness [55]. 
After polyplex formation the polymer surface can be equipped with shielding 
as well as targeting ligands that limit unwanted interactions and enable cell 
specific uptake. Besides from nucleic acid delivery, drug delivery in general, 
even in parallel [56], might be an option, due to optimization of structure and 
function that encompass optimal size and active and passive targeting. 
 
 
 
 
                  
 
 
 
 
Figure 3: Simplified depiction of compounds for polyplex formation. Top: T-shaped 
oligomer (ID: 1214) containing two oleic acids (OleA). Further elements of the oligomer: C: 
cysteine, H: histidine, Y: tyrosine, K: lysine, Stp: succinoyl-tetraethylene-pentamine, N3: 
azide function. Bottom: chemical structure of Stp on the left respectively of shielding and 
targeting structure HA-DBCO on the right. 
 
1.3. Shielding and targeting of polyplexes 
To circumvent unwanted interactions with blood components, provoked by 
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the polymers cationic charge [57], and extend vascular circulation [58], 
effective particle shielding is essential, as it can further enhance passive 
targeting and combined with right particle size of 10 to 200 nm [59], 
ultimately boost the tumor specific enhanced permeability and retention 
(EPR) effect [60, 61]. Finally, incorporated ligands, e.g. directed against 
certain receptors, enable active targeting for tumor cell specific 
internalization [62]. 
Adding passive shielding ligands to polyplexes can hamper renal filtration 
as well as undesired interactions within the bloodstream by masking the 
positive charge and guaranteeing ideal particle size [63, 64]. Also, nuclease-
initiated degradation processes are limited [65] and therefore enhance EPR 
effect by prolonged blood circulation time. Beneficial for increased tumor 
accumulation, accompanied by EPR effect, is the naturally enhanced 
permeability of tumor vessels due to gap junctions and pores between 
endothelial cells, which enables extravasation of the polyplexes [30-32]. In 
addition to increased vascularization of tumor tissue, lymphatic drainage is 
inadequate [66], increasing the amount of retained nanoparticles and 
minimizing particle removal. Though, a recent study suggesting that 
entering tumor tissue might be an active process, e.g. by binding to 
endothelial cells followed by trans-endothelial delivery and other 
mechanisms considered worthy of scientific study, has to be mentioned [33]. 
The aforementioned goals can be meet by the most common shielding 
agent polyethylene glycol (PEG) [67], although negative side effects like 
immunogenic reaction, e.g. production of antibodies directed against PEG, 
are described [68]. Because of these adverse immune reactions, scientists 
are looking for promising alternatives to PEGylation without the 
immunogenic disadvantages. 
Referring to Whitesides’ rules, ideal shielding candidates should contain 
polar functional groups with hydrogen bond acceptor characteristics, while 
hydrogen bond donor groups or net charge are absent [69]. Alternatives like 
repeats of proline-alanine-serine (PAS) [70, 71], oligosaccharides [72], the 
artificial polymer hydroxyethyl starch (HES) [73] fail to meet all the 
Whiteside criteria. Although polysarcosine (Psar), a polypeptoid, covers all 
of the aforementioned requirement and its protein resistance was validated 
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on different materials [74-76], still gene silencing was not achieved, while 
biodistribution revealed prolonged circulation time [77]. 
Another possible shielding candidate is the natural polysaccharide 
hyaluronic acid (HA), which can be found in the extracellular matrix and 
synovia of human body. Its shielding function results from its negative 
charge, which can reduce the cationic surface charge of the polymeric 
carriers and therefore limit nonspecific interactions with anionic blood 
components [78-80]. First studies give evidence of improved internalization 
and transfection with simultaneous low cytotoxicity in vitro [81] and in vivo 
[82]. Also, the formation of particles with an ideal maximum size of 200 nm 
is possible [83]. To sum that up, HA represents a promising shielding agent 
for in vivo evaluation. In addition, in contrast to the other mentioned agents, 
HA can act as receptor-ligand for cell uptake by endocytosis (see below). 
Though, currently the relationship between surface charge and therapy 
efficacy is only partly understood [84, 85]. Like previously described, 
polyplexes with negative or positive charge are prone to enhancing blood 
circulation time and hence tumor accumulation, due to reduced interaction 
with blood components. On the other hand, one has to note the influence of 
angiogenic tumoral endothelial cells that line the interior of vascular walls, 
and ultimately play an important role in intratumoral transport followed by 
possible gene silencing. The positive effect on binding and internalization of 
positively charged liposomes into endothelial cells [85] and therapeutic 
superiority, regarding tumor suppression, of cationic towards anionic or 
neutral particles, carrying a chemotherapeutic, could be demonstrated [84]. 
For that reason, the investigation of differently charged polyplexes, entailed 
by varying HA concentration, regarding their attraction to angiogenic 
endothelial cells in tumor tissue, is part of this work. 
Next to passive targeting via shielding agents in order to protect the surface 
[86] and enhance the EPR effect [61], active targeting by insertion of 
adequate ligands can be utilized to reach tumor tissue. Carriers have to fulfill 
two main goals: in the first place the siRNA polyplexes have to make their 
way to tumor tissue after systemic application, while maintaining their 
function [87], and in the second place be able to actively enter tumor cells 
with subsequent liberation of siRNA into the cytoplasm [66]. Specifically for 
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the second part, introduced active targeting ligands are widely used [88] and 
directed against fitting receptors. One advantage in tumor targeting is the 
overexpression of multiple receptors in tumor cells [89-91] that can 
represent possible objectives for suitable active targeting ligands. 
The folate receptor (FR) [92-95], epidermal growth factor receptor (EGFR) 
[96, 97] or transferrin receptor (TfR) [98-100] are frequently targeted, 
because of their presence in a multitude of cancer types. A wide range of 
targeting ligands like peptides [101], proteins comprising antibodies [102], 
aptamers or glycoproteins [103] is available [104]. 
All three aforementioned receptors were target of previous studies in our 
lab. Folic acid (FolA) and methotrexate (MTX) with its similar chemical 
structure can internalize tumor cells via FR specific uptake or reduced folate 
carriers (RFC) [105] and were successfully utilized as ligands [106-111]. 
Transferrin containing oligomers were capable of internalization, endosomal 
escape and successful subsequent transfection for gene delivery [112, 113]. 
EGFR that is typical for solid tumors [114], is target for many antitumoral 
drugs, especially directed against lung cancer [115, 116]. The peptide GE11 
exhibits one possible targeting ligand directed against EGFR for tumor cell 
specific oligomer delivery [117, 118], while avoiding mitogenic side effects 
[119].  
In this thesis we focused on the natural polymer hyaluronic acid (HA) as a 
combined shielding and targeting agent as designed by Jie Luo (PhD 
student at Pharmaceutical Biotechnology, LMU). After siRNA incorporation, 
the azido-modified polyplex surface is functionalized with HA coupled to 
dibenzocyclooctyne (DBCO) by copper-free click reaction with the azido 
functionality (illustrated in Figure 4) [51]. HA can enter the cell via receptor-
mediated endocytosis, employing its primary receptor, the transmembrane 
glycoprotein CD44 [120]. CD44 also represents an biomarker for cancer 
stem cells (CSC) that have multiple effects on tumor development [121], 
demonstrating the influence it can have by tumor targeting [122]. 
Furthermore, CD44 overexpression is reported for different cancer types 
comprising lung [123], pancreas [124] and breast tumors [125] compared to 
healthy tissue. Additionally, HA itself is biocompatible, provokes no immune 
response, which are in combination with its hydrophilic character, valuable 
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properties [126]. Several clinical trials focusing on CD44 as target structure 
[127-129], highlight the potential of HA as its main ligand. 
 
Figure 4: Simplified depiction of the polyplex creation. HA shielded and targeted 
polyplexes containing siRNA are formed via click-chemistry, which is enabled by the azide 
function and HA modified with DBCO. Before this surface functionalization, the cationic 
backbone can bind negatively charged siRNA. Depending on the amount of contained 
anionic HA, cationic or anionic polyplexes are created. The figure is provided by Jie Luo 
(PhD student at Pharmaceutical Biotechnology, LMU).  
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2. Aims of the thesis 
The thesis aimed at evaluation of the in vivo characteristics of siRNA 
nanoparticles developed for specific delivery into tumor tissue in a human 
tumor xenograft mouse model.   
For that purpose, nanoparticles formulated with hyaluronic acid as shielding 
and targeting ligand of varying charge, depending on the amount of HA, 
were first to be tested in a human HUH7 hepatocellular carcinoma mouse 
model for their systemic biodistribution pattern, especially concerning tumor 
delivery.  
In addition, efficacy of EG5 target gene silencing after twofold intravenous 
application of the different nanoparticles had to be evaluated (in 
collaboration with Jie Luo, PhD student at Pharmaceutical Biotechnology, 
LMU). 
Furthermore, in vivo cytotoxicity of the different siRNA nanoparticles was to 
be determined via analysis of blood plasma for liver (alanine 
aminotransferase and aspartate aminotransferase) and renal parameters 
(blood urea nitrogen and creatinine).  
Moreover, histology including immunostaining and 3D-reconstruction was 
to be performed (in collaboration with Mochen Cui, PhD student at Center 
for Neuropathology and Prion Research, LMU) to gain deeper 
understanding of the tumoral distribution pattern. 
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II. MICE, MATERIALS AND METHODS 
1. Mice 
1.1. Mouse strain 
Female Rj: NMRI-Foxn1nu/Foxn1nu mice were purchased from Janvier Labs 
(Le Genest-St-Isle, France). As a result of a mutation in the Foxn1nu gene, 
this outbred mouse strain lacks a thymus and therefore has no mature T-
lymphocytes, whereas B-lymphocytes and other cells of the innate immune 
system are present and functionally working. These mice are nude, due to 
an impaired keratinization of hair follicle and epidermis. They are therefore 
an ideal model for bioimaging experiments and because of their incomplete 
immune system perfect for the usage in xenograft tumor models. 
1.2. Housing conditions 
Mice were purchased at an age of 5 weeks and acclimated for 7 days before 
starting experiments. Animals were housed in isolated ventilated cages (IVC 
type II, Tecniplast) under specific pathogen-free conditions, which were 
controlled as described in 1.3. A 12 h day / night interval was maintained, 
temperature and air humidity were kept constant at 24 - 26°C, respectively 
50 - 70% and checked daily. Light and sound intensity were set to 200 Lux, 
respectively 40 dB. The stocking density of each cages varied from 2 to 5 
mice. Cages were furnished with dust-free bedding (ABEDD Vertriebs 
GmbH, Österreich) that was changed once per week, whereas sterilized 
food (ssniff Spezialdiäten, Soest, Germany) and water were available ad 
libitum. The cages were enriched with cottages, wooden tubes and nest 
building material. All parameters were maintained according to §11 of the 
German Animal Welfare Act [130]. 
 
1.3. Health monitoring 
Every 12 weeks health monitoring of the animal facility was conducted. For 
this reason, sentinel mice were held in the same animal facility and weekly 
received bedding material and food from all animal cages that were part of 
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a running experiment. Every 3 months, a complete health analysis of two 
sentinel mice was done by an external laboratory (mfd Diagnostics GmbH, 
Wendelsheim, Germany). 
 
2. Materials 
2.1. Cell culture 
Cell culture was done by Jie Luo (PhD student at Pharmaceutical 
Biotechnology, LMU). 
Material Source 
HUH7 - wildtype cells 
(human hepatocellular carcinoma 
cells) 
JCRB Cell Bank (Osaka, Japan)  
DMEM 1 g/l glucose medium Invitrogen (Karlsruhe, Germany) 
FCS (fetal calf serum) Invitrogen (Karlsruhe, Germany) 
PBS (phosphate buffered saline) Biochrom (Berlin, Germany) 
TE (trypsin EDTA) solution Biochrom (Berlin, Germany) 
L-alanyl-L-glutamine Biochrom (Berlin, Germany) 
Cell culture plates and flasks TPP (Trasadingen, Switzerland) 
 
2.2. In vivo experiments 
The experiments including perfusion were performed in cooperation with 
Mochen Cui (PhD student at Center for Neuropathology and Prion 
Research, LMU) 
Material Source 
Isoflurane CP® CP-Pharma (Burgdorf, Germany) 
Xylavet  CP-Pharma (Burgdorf, Germany) 
Ketamine WDT (Garbsen, Germany) 
Bepanthen® 
Bayer Vital GmbH (Leverkusen, 
Germany) 
Syringes, needles BD Medical (Heidelberg, Germany) 
Multivette (EDTA-coated tubes) Sarstedt (Nümbrecht, Germany) 
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HBG (HEPES buffered 5% 
glucose, pH 7.4) 
HEPES: Biomol (Hamburg, Germany) 
glucose monohydrate: Merck 
(Darmstadt, Germany) 
 
2.3. Histology 
Immunostaining and 3D reconstruction were done by Cui Mochen (PhD 
student at Center for Neuropathology and Prion Research, LMU) and Jie 
Luo (PhD student at Pharmaceutical Biotechnology, LMU). 
Material Source 
PBS (phosphate buffered saline) Biochrom (Berlin, Germany) 
PFA (paraformaldehyde)  Sigma-Aldrich (Munich, Germany) 
DyLight 488 labeled Lycopersicon 
esculentum (tomato) lectin 
Vector Laboratories (Burlingame, 
CA, USA) 
BSA (bovine serum albumin) VWR (Radnor, PA, USA) 
mounting medium H-1400 Vector Laboratories (Burlingame, 
CA, USA) 
confocal microscope Zeiss 
LSM780 
Zeiss (Oberkochen, Germany) 
 
2.4. Oligomer 
The oligomer 1214 (illustrated in Figure 5) was synthesized Jie Luo (PhD 
student at Pharmaceutical Biotechnology, LMU). 
ID Sequence Topology 
1214 K(N3)-C-Y3-(H-Stp)2-H-K(K(OleA)2)-H-(Stp-H)2-Y3-C T-shape 
Figure 5: Illustration of polymer 1214. 
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2.5. siRNAs  
siRNA Source 
siCtrl 
AuGuAuuGGccuGuAuuAG dTsdT 
CuAAuAcAGGCcAAuAcAU dTsdT 
Axolabs (Kulmbach, Germany) 
siEG5 
ucGAGAAucuAAAcuAAcu dTsdT 
AGUuAGUUuAGAUUCUCGA dTsdT 
Axolabs (Kulmbach, Germany) 
siAHA1-Cy7 
GGAuGAAGuGGAGAuuAGu dTsdT 
(Cy7)(NHC6)ACuAAUCUCcACUUcAUCC 
dTsdT 
Axolabs (Kulmbach, Germany) 
siAHA1-Cy3 
ACuAAUCUCcACUUcAUCC dTsdT 
(Cy3)(NHC6)GGAuGAAGuGGAGAuuAGu 
dTsdT 
Axolabs (Kulmbach, Germany) 
* Capital letters: standard RNA ribonucleotides (A: Adenylate, G: Guanylate, 
C: Cytidylate, U: Uridylate); small letters: 2’methoxy-RNA; dT: deoxy-
thymidine; s: phosphorothioate linkage 
Conjugates were provided by Jie Luo (PhD student at Pharmaceutical 
Biotechnology, LMU). 
2.6. Compounds 
Hyaluronic acid (HA) Lifecore Biomedical (Chaska, MN, USA) 
The amount of DBCO on HA is described as molar equivalents (equiv.) 
related to the cationic oligomer (mol/mol). 
2.7. Instruments 
Name Manufacturer 
Caliper DIGI-Met Preisser (Gammertingen, Germany) 
IVIS Lumina Caliper Life Science (Rüsselsheim, Germany) 
Microtome Leica 
VT1000S  
Leica (Wetzlar, Germany) 
Confocal microscope 
Zeiss LSM780 
Zeiss (Oberkochen, Germany) 
 
II. Mice, Materials and Methods     17 
2.8. Software 
Name Manufacturer 
GraphPad Prism 5 
software 
GraphPad Software (San Diego, USA) 
Living Image 3.2 Caliper Life Science (Rüsselsheim, Germany) 
Imaris 9.0.1 Bitplane (Belfast, UK) 
 
3. Methods 
3.1 . Cell culture 
Human hepatocellular carcinoma cells (HUH7) were cultured in Dulbecco’s 
modified Eagle’s medium (DMEM) supplemented with 10% fetal calf serum 
(FCS), 1 g/L glucose, 4 mM stable glutamine, 100 U/ml penicillin and 100 
µg/ml streptomycin. The cell line was cultured at 37 °C and 5 % CO2 in an 
incubator with a relative humidity of 95%. 
3.2. In vivo experiments 
HUH7 tumor cells were suspended in 150 µL PBS and injected 
subcutaneously into the left flank of 6-week-old mice using a 27G cannula. 
Inoculation was done under inhalation anesthesia (5% isoflurane in oxygen 
for induction and 2.5% for maintenance). 
Animal weight was determined every second day until tumors became 
measurable and from then on daily. Tumor sizes were measured by caliper 
and calculated using the following formula: 0.5 × longest diameter × shortest 
diameter2 [131]. Intravenous injections into the lateral tail veins were 
performed using a restrainer and prior to the injection tails were warmed in 
lukewarm water (~37°C) to depict the veins more clearly. 
Euthanasia by cervical dislocation was performed under isoflurane narcosis 
when previously determined abort criteria occurred (for example a tumor 
diameter of 12 mm or a severely affected well-being). 
All animal experiments were approved by the district government of Upper 
Bavaria (reference numbers: 55.2-2532.Vet_02-19-020 and 55.2-1-54-
2532-233-13) in accordance with the guidelines of the German Animal 
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Welfare Act [130]. 
3.2.1. In vivo biodistribution studies 
6-week-old mice were injected subcutaneously into the left flank with 5 × 
10⁶ HUH7 tumor cells. As soon as the tumors reached 500 mm³, animals 
were randomly divided into 7 groups (n=3). They received a single i.v. 
injection with 250 µL of 1214 with 0.04 up to 1.0 equiv. of HA-DBCO 
modification comprising 50 µg Cy7-labeled (50%) siRNA at N/P 12. Using a 
CCD camera NIR fluorescence bioimaging was conducted under inhalation 
anesthesia with 3% isoflurane in oxygen at different time points for 24 h. 
After the last timepoint mice were sacrificed and images of tumor and 
organs were obtained. For the image evaluation color bar scales were 
equalized and efficiency of fluorescence signals was analyzed using the 
Living Image software 3.2. 
3.2.2. Clinical blood parameters 
During the EG5 gene silencing studies blood was obtained from all mice by 
final heart puncture after euthanasia by cervical dislocation. The blood 
samples were gathered in EDTA-coated tubes and centrifuged at 3000 rpm 
for 7 minutes to isolate blood plasma. The supernatant was analyzed for 
liver (alanine aminotransferase and aspartate aminotransferase) and renal 
parameters (blood urea nitrogen and creatinine) in the Clinic of Small 
Animal Medicine, Faculty of Veterinary Medicine, LMU. Untreated mice 
injected with HBG served as reference. 
3.2.3. In vivo gene silencing study  
6-week-old mice were injected subcutaneously with 5 × 10⁶ HUH7 cells and 
divided into 5 groups (n=5) when tumors reached a size of 500 mm³. Mice 
were injected i.v. with a volume of 250 µL of 1214 with 0.1 equiv. of HA-
DBCO modification respectively 0.8 equiv. of HA-DBCO modification 
comprising 50 µg of siCtrl respectively siEG5 at N/P 12. Control animals 
received the solution buffer HBG. The previously described formulations 
were administered twice with a twenty-four hours interval. 24h after the 
second and last injection the mice were sacrificed. In parallel with 
euthanasia blood was obtained by heart puncture for the following clinical 
biochemistry (see 3.2.3). 
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Tumors were gathered to extract RNA by using Trifast (Peqlab, Erlangen, 
Germany) according to the manufacturer’s protocol. Gene silencing 
efficiency was evaluated by Jie Luo (PhD student at Pharmaceutical 
Biotechnology, LMU). Quantitative real-time polymerase chain reaction 
(qRT-PCR) was performed to measure the EG5 mRNA level in tumor tissue. 
Total RNA was isolated followed by reverse transcription using qScriptTM 
cDNA Synthesis Kit (Quanta Biosciences, Beverly, MA, USA). Quantitative 
RT-PCR was performed in triplicates on a LightCycler 480 system (Roche, 
Mannheim, Germany) using UPL Probes (Roche, Mannheim, Germany) 
and Probes Master (Roche, Mannheim, Germany) with GADPH as 
housekeeping gene. The following probes and primer sequences were 
used: human GAPDH (ready-to-use in UPL, UPL Probe #45), and human 
EG5 (UPL Probe #53) (forward: CATCCAGGTGGTGGTGAGAT, reverse: 
TATTGAATGGGCGCTAGCTT). Results were analyzed by the ΔCT 
method. CT values of GAPDH were subtracted from CT values of EG5. ΔCT 
values of treated animals were calculated as percentage of HBG treated 
control animals. 
3.2.4. Histological evaluation 
5 × 10⁶ HUH7 cells were injected subcutaneously into the left flank of 6-
week-old mice. When tumors reached a size of 500 mm³, animals were 
divided into 6 groups (n=2) and injected intravenously into tail vein with 250 
µL 1214 without HA-DBCO modification, cationic (1214 with 0.1 equiv. of 
HA-DBCO modification) or anionic (1214 with 0.8 equiv. of HA-DBCO 
modification) polyplexes comprising 50 µg of siCtrl spiked with 50% of Cy3-
labeled siRNA at N/P 12. 5 respectively 45 min after i.v. injection the 
perfusion process was performed under intraperitoneal ketamine-xylazine 
(ketamine: 100 mg/kg, xylazine: 10 mg/kg) anesthesia. By heart puncture 
the animals were perfused with phosphate buffered saline (PBS), 
afterwards with paraformaldehyde (PFA) for 3 minutes, followed by blocking 
with bovine serum albumin (BSA) and staining with 50 ml DyLight 488TM 
labeled Lycopersicon esculentum lectin (20 µg/ml, diluted in PBS) [132]. In 
a final, step mice were perfused with BSA again. All steps were conducted 
for 1 minute with a flow rate of 10 ml/min and used chemicals were diluted 
to 1% in PBS, if not stated otherwise. 
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With perfusion being finished tumor and organs were harvested and cut by 
vibratome into 50 µm thick slices. Afterwards free-floating sections were 
collected from water bath, mounted with antifade mounting medium and 
scanned within 12 h in a Z-stack manner with 1 µm interval using a confocal 
microscope system. Corresponding 3D reconstruction and quantitative 
analysis was done using the Imaris 9.0.1 software. Perfusion and 
microscopic examination were performed by Mochen Cui (PhD student at 
Center for Neuropathology and Prion Research, LMU) and Jie Luo (PhD 
student at Pharmaceutical Biotechnology, LMU). 
3.3. Statistical analysis 
Results are depicted as mean + S.E.M (standard error of the mean). 
Statistical analysis was evaluated with unpaired students t-test employing 
GraphPad Prism™. P-values smaller than 0.05 were regarded as significant 
(*p < 0.05; **p < 0.01; ***p < 0.001; ns = no significance).
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III. RESULTS 
To achieve effective siRNA delivery, an appropriate carrier system is crucial. 
For this purpose, our working group can resort to a library of about 1400 
sequence-defined oligomers. In this section a siRNA transporter system, 
modified with HA as shielding and targeting agent, is assessed regarding 
biodistribution and especially tumor accumulation. Furthermore, gene 
silencing efficiency was investigated and immunostaining as well as 3D-
reconstruction were performed to gain deeper understanding of in vivo 
distribution on a histological level. 
After in vitro screening of different structures, the oligomer 1214 was chosen 
for further in vivo evaluation due to its superior stability (demonstrated by 
agarose gel electrophoresis) and transfection efficacy for siRNA (Jie Luo, 
unpublished data). The necessary surface modification via the azide 
function with HA-DBCO for efficient shielding and targeting is depicted in 
Figure 4. The amount of DBCO on HA is described as molar equivalents 
(equiv.) related to the cationic oligomer (mol/mol) and leads to the formation 
of cationic or anionic nanoparticles. 
All experiments were performed with HUH7, a human hepatocarcinoma 
derived cell line that overexpresses the HA susceptible CD44 receptor. 
Oligomers for all experiments were generated by Jie Luo (PhD student at 
Pharmaceutical Biotechnology, LMU). Elisa Hörterer (PhD student at 
Pharmaceutical Biotechnology, LMU) assisted during the gene silencing 
and histology studies. The perfusion as well as the histological evaluation 
were performed by Mochen Cui (PhD student at Center for Neuropathology 
and Prion Research, LMU) and Jie Luo. All experiments were performed in 
NMRI nude mice. 
1. In vivo biodistribution studies 
Because a multitude of parameters influences biodistribution of siRNA 
polyplexes, near infrared imaging (NIR) was conducted to analyze 
distribution regarding tumor accessibility. 
CD44 receptor positive HUH7 tumor cells were used and mice were injected 
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i.v. with 1214 formulations at a tumor size of 500 mm³. 1214 formulations 
contained 50 µg of 50% Cy7-labeled siRNA and the following equiv. of HA-
DBCO: 0.04, 0.1, 0.2, 0.4, 0.8 and 1.0. Validated by zeta potential 
measurement (Jie Luo, unpublished data), equiv. of HA-DBCO of 0.04, 0.1 
and 0.2 result in a cationic net charge, whereas higher amounts of HA lead 
to negatively charged particles. 1214 without HA-DBCO modification served 
as control. 
After i.v. injection, fluorescent Cy7 dye was observed via in vivo imaging of 
isoflurane anesthetized mice. Eight time points were recorded up to 24 h 
post injectionem and additionally organs and tumor were imaged ex vivo 
after euthanasia and subsequent extraction. 
Figure 6 shows the biodistribution of formulations. In comparison to the 
control group the cationic nanoparticles with equiv. of 0.04 up to 0.2 of HA-
DBCO (illustrated in Figure 6, A) featured similar distribution pattern. For 
the equiv. of 0.04 HA slighty stronger signal is visible after 2 and 3h, but all 
cationic formulations exhibit comparably weak fluorescence after 4 and 24h. 
It is noteworthy that only the equiv. of 0.1 and 0.2 HA-DBCO modification 
display a signal in tumor tissue up to 1h (indicated by yellow circle), while 
the higher HA concentration of 0.2 equiv. achieves tumor accumulation only 
in one out of three mice and overall tumor signal is significantly weaker. For 
later timepoints (> 1h) the tumor signal vanishes without resurfacing 
(indicated by red circle). These findings coincide with the ex vivo images 
(illustrated in Figure 6, C, bottom row) that show no fluorescence signal in 
harvested tumor tissue (indicated by red circle). 
On the contrary, the negatively charged formulations of 1214 modified with 
equiv. of 0.4 up to 1.0 of HA-DBCO (illustrated in Figure 6, B) demonstrate 
a diminished overall full-body fluorescence signal with minor differences in 
between the three groups, compared to animals injected with 1214 without 
HA modification and the cationic formulations, but nevertheless a strong 
signal in the lung area, equal or even slightly more intense than in the 
cationic formulations at the same timepoint, is visible after 4h. 
Consequently, for anionic particles no accumulation in tumor tissue is 
detectable in vivo or ex vivo (indicated by red circle in Figure 6, B and C). 
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In sum, cationic formulations evinced slightly stronger full-body 
fluorescence signal compared to their negatively charged counterparts. 
Additionally, two cationic formulations were detectable in the tumor area, 
but eliminated relatively fast after 1h. Regarding tumor targeting, in the 
direct comparison of 0.1 to 0.2 equiv. of HA-DBCO, the lower cationic 
concentration of 0.1 equiv. of HA proved to be superior by exhibiting 
stronger tumor signal in more (2 out of 3) mice up to 1h. Consistent with 
these findings, the ex vivo images taken after 3h did not show signs of 
intratumoral fluorescence. 
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Figure 6: Distribution of polyplexes in HuH7 tumor bearing mice. NIR fluorescence 
bioimaging of polyplexes of 1214 containing 50% Cy7-labeled siRNA with varying equiv. of 
HA-DBCO modification and without HA-DBCO modification as control, was performed. 
Animals were imaged immediately after i.v. injection and additional images were taken after 
15 and 30 min and 1, 2, 3, 4 and 24 h. In each group all 3 animals were measured up to 1 
h, but only two mice were imaged after 2 and 3 h, whereas only one mouse after 4 and 24 
h. After euthanasia organs were harvested and imaged, but only timepoint 3 h is displayed. 
For each group and timepoint, images of one representative animal are displayed. To 
guarantee best visibility of the tumor site on the left flank (indicated by red dotted circles) 
animals are presented in lateral position. Yellow dotted circles are used for images with 
strong signal in area of tumor site, indicating successful delivery of formulation into tumor 
tissue. Color scale (efficiency) had a minimum of 1.4 e-5 and a maximum of 2.5 e-4 
fluorescent photons/incident excitation photon. A) Control and cationic formulations B) 
Anionic formulations C) Ex vivo images of organs after 3h: 1: lung, 2: tumor (indicated by 
red dotted circles), 3: liver, 4: heart, 5: spleen, 6: kidneys. 
 
2. Clinical blood parameters 
Due to excessive accumulation in tissue, other than tumor, undesired side 
effects can occur. Therefore, to register the biocompatibility and exclude 
immune response of the siRNA polyplexes after systemic application, blood 
was tested for kidney and liver parameters, as they might indicate unwished 
adverse effects, due to their involvement in drug degradation and 
elimination. 
The values of liver parameters AST (aspartate aminotransferase) and ALT 
(alanine aminotransferase) and kidney parameters BUN (blood urea 
nitrogen) and creatinine (illustrated in Figure 7) are unobtrusive, suggesting 
that the formulations were tolerated well by the mice. They are within normal 
III. Results     25 
range, compared to the control group, and are in accordance with values in 
literature and the standard values provided by the supplier, Janvier [133]. 
 
Figure 7: Clinical blood parameters. Blood was collected at the end of the gene silencing 
experiment from mice injected with 1214 with 0.1 equiv. of HA-DBCO modification and 
1214 with 0.8 equiv. of HA-DBCO modification containing siCtrl or siEG5. HBG served as 
an untreated control group. The plasma extraction was followed by analysis for liver (AST, 
ALT) and kidney (BUN, creatinine) parameters in the Clinic of Small Animal Medicine, 
Centre for Clinical Veterinary Medicine, Faculty of Veterinary Medicine, LMU Munich. 
Depicted is the mean + S.E.M. of 5 mice per group. 
 
3. In vivo gene silencing study 
To research specific uptake into tumor cells, biodistribution imaging via Cy7 
fluorescence is insufficient. For that reason, a gene silencing experiment 
was performed to investigate, whether delivery into the cytoplasm and 
subsequent target gene knockdown is possible. In this follow-up experiment 
the gene silencing capacity of promising anionic and cationic formulations 
was assessed. As cationic respectively anionic representatives 1214 
modified with 0.1 respectively 0.8 equiv. of HA-DBCO were selected, since 
the cationic formulation exhibited tumor accumulation until 1 h after i.v. 
injection, while no anionic formulation could reach tumor tissue, but still 0.8 
equiv. of HA-DBCO was most convincing regarding in vitro data (Jie Luo, 
unpublished data). Polyplexes were formulated with siRNA directed against 
the antitumoral model gene EG5. Targeting of EG5, which is a kinesin-
related motor protein gene participating in the self-assembly of the 
microtubule-based mitotic spindle [134], leads to the arrest of cell mitosis. 
The control group was injected with HBG. 
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Animals were inoculated with HUH7 cells and split into 5 groups (n=5), as 
soon as tumors reached a size of 500 mm³. They received twofold i.v. 
injections into the tail vein with one day break between the administrations. 
24 h after the second treatment, mice were euthanized and tumors were 
removed for subsequent RNA isolation and qRT-PCR analysis of mRNA 
levels of EG5. EG5 mRNA level of treated mice is shown in comparison to 
untreated HBG group (depicted in Figure 8). 
Tumoral EG5 mRNA expression was significantly downregulated (~80%) 
after injection of positively charged 1214 modified with 0.1 equiv. of HA-
DBCO + siEG5. The anionic formulation of 1214 modified with 0.8 equiv. of 
HA-DBCO + siEG5 provoked only minor EG5 gene knockdown of about 
10%. For both, the anionic and the cationic formulation, the analog control 
formulation containing siCtrl did negligibly influence mRNA levels (depicted 
in Figure 8). 
  
Figure 8: Gene silencing efficiency of cationic and anionic 1214 formulations in 
HUH7 tumor bearing mice. Groups (n=5) were injected with 1214 with 0.1 respectively 
0.8 equiv. of HA-DBCO modification containing siEG5 or siCtrl. Animals were euthanized 
24 h after second i.v. injection and tumors were analyzed by qRT-PCR for mRNA levels of 
EG5 gene. EG5 gene level (mean + S.E.M.) is expressed in % of untreated HBG control, 
defined as 100%. qRT-PCR was performed by Jie Luo (PhD student at Pharmaceutical 
Biotechnology, LMU). 
 
Additionally, the animal weight was measured daily to monitor animal well-
being, especially during treatments. No severe weight loss and therefore no 
negative effect of the injections could be detected. 
To sum this up, only the cationic formulation of 1214 modified with 0.1 equiv. 
of HA-DBCO + siEG5 did significantly hamper mRNA expression, while no 
negative side effects could be observed via clinical biochemistry parameters 
and body weight. 
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4. Histological evaluation 
Apart from proving the successful gene delivery via PCR to determine EG5 
mRNA expression, analysis on a histological level can provide information 
about charge dependent tumoral distribution patterns. In the related 
experiment two fluorescent dyes were employed: DyLight 488TM that 
specifically stains endothelial cells of blood vessels, and Cy3 dye for exact 
particle identification. At 5 respectively 45 min after intravenous injection of 
unmodified 1214, 1214 modified with 0.1 or 0.8 equiv. of HA-DBCO labeled 
with 50 µg of siCtrl spiked with 50% of fluorescent dye Cy3, into two mice in 
each group, perfusion and histological tissue preparation were performed 
according to method 3.2.5. Analysis and processing were done by confocal 
laser scanning microscopy (CLSM) combined with Imaris software. The 
distribution of cationic and anionic HA polyplexes of 1214 is shown in Figure 
9. 
After 5 min, only the cationic formulation containing 0.1 equiv. of HA-DBCO 
exhibits significant endothelial attachment in tumor vessels (Cy3 labeled 
particles are depicted in red, endothelial cells of vessels in green), whereas 
the anionic formulation of 0.8 HA respectively the control group without HA 
modification show next to no respectively rather weak intravascular Cy3 
expression. Looking at the merged image of the positively charged 
formulation of 1214 containing 0.1 equiv. of HA-DBCO, it becomes obvious 
by macroscopic inspection that the vast majority of particles seems to 
remain within tumor vessels. 
On the contrary, the later timepoint of 45 min for 1214 containing 0.1 equiv. 
of HA-DBCO reveals a shift from localization mainly inside the vessels 
towards surrounding tissue. After 45 min the majority of particles was able 
to pass the vessel wall and penetrate into tumor tissue. 
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Figure 9: Distribution of cationic and anionic 1214 polyplexes in HUH7 tumors on a 
histological level. Six Groups (n=2) were injected with unmodified 1214 (A), 1214 
modified with 0.1 (B, D, E) or 0.8 (C) equiv. of HA-DBCO labeled with 50 µg of siCtrl spiked 
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with 50% of fluorescent dye Cy3 (exhibiting red fluorescence signal). 5 (A, B, C) 
respectively 45 min (D, E) after application, perfusion, involving DyLight 488TM labeled 
Lycopersicon esculentum tomato lectin (exhibiting green fluorescence signal) for staining 
of vessels [132], was done. For each formulation the fluorescence of Cy3 and DyLight 
488TM after 5 min (A, B, C) is depicted, as well as a merged image combing both 
fluorescences. For the later timepoint of 45 min (D, E), only 1214 modified with 0.1 equiv. 
of HA-DBCO is presented. This is due to the fact that it is the only formulation being present 
in tumor tissue in a relevant dose after 5 min (B). The scale bar indicates 20 µm. The figure 
is adapted from Luo et al., manuscript in preparation.  
 
Figure 10: Quantitative data analysis of tumor tissue for cationic formulation. This 
illustration depicts the distance of particles of 1214, modified with 0.1 equiv. of HA-DBCO 
and labeled with Cy3, from tumoral blood vessels to investigate time-dependent distribution 
after 5 (orange curve) and 45 (red curve) min. The y-axis presents the percentage of Cy3 
signal compared to a total signal of 100%. The figure is adapted from Luo et al., manuscript 
in preparation. 
Analysis of quantitative distribution data (illustrated in Figure 10) reveals 
that with elapsing time the Cy3 signal in tumor tissue increases, while it 
declines inside respectively in close proximity to blood vessels. After 5 min 
more than 60% of the nanoparticles are located inside the tumor vessels, 
whereas after 45 min less than 20% can be found intravascular and the 
largest part (> 80%) are at least 10 µm away from vessels. 
In conclusion, relevant accumulation in tumor vessels and tissue was only 
obtained by the cationic formulation of 1214 with HA, while the control group 
and the anionic counterpart could not achieve tumor delivery, which is in 
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accordance with the findings of the biodistribution studies and the gene 
silencing experiment. In addition, the tumoral distribution for 0.1 equiv. of 
HA develops over time, resulting in an increased nanoparticle concentration 
in tissue compared to blood vessels after 45 min.
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IV. DISCUSSION 
With the first siRNA drugs being approved for hereditary ATTR amyloidosis 
and acute intermittent porphyria (AIP) and many more currently undergoing 
clinical trials [135, 136], the potential of siRNA-based therapies is 
evidenced. Nevertheless delivery of siRNA into target tissue presents an 
obstacle, due to its poor pharmacokinetics [137-139]. A solution to this issue 
is effective carrier systems to increase stability and by that enhance blood 
circulation time, as well as achieve specific targeting to desired tissues. Our 
working group established a library of about 1400 sequence-defined 
oligomers that can serve as transporters for nucleic acids like siRNA. Their 
advantages lie in reduced particle size and masking the positively charged 
backbone, therefore limiting cell toxicity [17]. Several recent studies 
underline the potential of these carriers concerning nucleic acid 
transportation [106, 108, 111, 118]. Still, stability and renal excretion after 
systemic application represent great hurdles for these carriers that could be 
solved by continuous revision and improvement with beneficial features like 
surface functionalization (e.g. by employing click-chemistry). 
The oligomer 1214 was selected for siRNA delivery to a subcutaneous 
tumor model after intravenous injection. Furthermore, modification with 
hyaluronic acid (HA) aimed at tumor tissue selective accumulation by 
passive and active targeting with constant biocompatibility. 
1. Tumor targeting via biodistribution studies 
PEG is used for the last three decades to prolong circulation time in blood 
by protecting the nanoparticles from quick elimination by the kidney and 
adverse immune reactions, both resulting in decreased delivery and 
accumulation in target tissue [63, 67]. An alternative shielding agent, the 
natural polysaccharide HA [78-80] that does not exhibit pronounced 
immunogenic reactions, could additionally serve as an active targeting 
ligand by binding to the receptor CD44 [127-129]. The required 
overexpression of CD44 is reported for many tumoral cell lines (e.g. HUH7) 
and could assist in tumor selective delivery. Via an azide function as a 
functional domain the oligomer can subsequently be modified with 
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cyclooctyne derivates (e.g. DBCO) [140] and by that smoothly functionalize 
the polyplex via click-chemistry. Other functional groups like thiols show 
promising gene silencing efficacy in vitro, but in vivo present disadvantages 
mainly regarding stability [117, 141, 142], while cyclooctynes can react with 
azide groups enabling efficient coupling without by-products and copper 
related cytotoxicity [51, 52, 143]. 
Hence, oligomeric formulations of 1214 modified by click-chemistry with 
differing amounts of HA were evaluated in a biodistribution experiment for 
this thesis. 
HA allowed efficient shielding of the oligomer and the linked siRNA, 
indicated by significant signal after 24h. Although in vitro agarose gel 
electrophoresis (Jie Luo, unpublished data) suggested equal stability for all 
anionic and cationic particles, with amounts bigger than 0.2 equiv. of HA-
DBCO modification, the result in vivo is weaker full-body biodistribution. This 
might be due to decreased in vivo stability of the anionic formulations, 
because of a critical threshold of HA that was exceeded. 0.1 and 0.2 equiv. 
of HA-DBCO seem to represent the ideal amount of HA, which can 
effectively shield the cationic backbone from negatively charged blood 
components and thereby facilitate significant retention in tumor tissue. 
However, this objects previous efforts to create anionic nanoparticles to 
circumvent rapid plasma clearance involving undesired interactions with 
blood components. But apart from negative charge other factors like the 
ability to penetrate capillaries of other tissues, the hepatic metabolization of 
the nanoparticles and the renal clearance of degradation products, play a 
role in the elimination from plasma [144]. Our biodistribution experiments 
demonstrated that overall cationic charge is tolerable, if the shielding agent 
can partly hide the cationic charge through its anionic character. This partly 
shielding enables accumulation in tumor tissue with 0.1 equiv. of HA 
displaying strongest direction to site of action. Nevertheless, comparably 
fast tumoral clearance resulting in no tumor signal after 2 h, indicates that 
necessary efforts have to be made regarding further modification of the 
oligomer to prolong tumoral retention. Furthermore, biodistribution only 
gives information about tumor accumulation, but ignores exact siRNA 
location and functionality. 
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2. Gene silencing efficiency in vivo 
The biodistribution experiments present the effective usage of HA for 
surface shielding after systemic administration. Due to passive targeting 
e.g. via the EPR effect by adequate nanoparticle size [145], enhanced blood 
circulation and permeable vessels next to diminished clearance by the 
lymph system, tumoral delivery is possible [146]. After targeting the site of 
action, the active substance has to be delivered into the cytosol. The actual 
uptake into tumor cells can be directed via active targeting of the receptors, 
e.g. CD44. In the presented experiments, the HA modified nanoparticles 
can selectively bind to solid HUH7 tumors overexpressing CD44 [147] and 
internalize via receptor-mediated endocytosis. 
The formulation of 1214 with varying equiv. of HA-DBCO was examined 
regarding its potential to silence the target gene EG5. For that purpose, 
siRNA directed against EG5 mRNA was introduced. Eglin 5 or kinesin 
spindle protein (KSP), the so-called EG5, plays a vital role in mitosis during 
the self-assembly of the microtubule-based spindle [148]. Although it is a 
valuable target in cancer therapy, due to its knockdown leading to inhibition 
of cell division and finally cell death, in our study it only served as a marker 
gene to register successful internalization and release into cytoplasm of 
siRNA integrated into nanoparticles with subsequent reduced expression of 
the target gene EG5. 
Directing 1214 with 0.1 equiv. of HA-DBCO towards EG5, resulted in a gene 
silencing effect of about ~80%, surpassing the efficiency of ~60% 
respectively 65% of previous studies [108, 111]. Conversely, the anionic 
formulation with 0.8 equiv. displayed EG5 gene expression of about 90%, 
being tantamount with a gene knockdown of only ~10%. The analog siCtrl 
formulations showed only minor reduction of EG5 expression making 
unspecific gene silencing by the polyplexes themselves highly unlikely. The 
data suggests that the cationic HA formulation was able to enter tumor cells 
more effectively and therefore deliver the complexed siRNA into the cytosol 
resulting in significant EG5 gene knockdown. In combination with the 
findings from the biodistribution studies, we can state that the anionic 
formulation, including 0.8 equiv. of HA-DBCO, is explicitly inferior 
concerning tumor delivery and conditional siRNA uptake and cytosolic 
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release into HUH7 cells. The novel assumption that uptake into tumor tissue 
is an active process mediated by endothelial cells [33] might be an 
explanation. Attachment to the negatively charged glycocalyx of endothelial 
cells [149] is a prerequisite that can be met by cationic nanoparticles more 
easily [85]. Another hypothesis is the binding of cationic nanoformulations 
to anionic lymphocytes and subsequent transportation into tumor tissue 
[150-152]. Though anionic net charge is considered advantageous 
regarding parameters like circulation time and shows comparable 
transfection efficacy in vitro, the cationic formulation prevails in our 
experiments. This can result from increased tumor accumulation because 
of its cationic charge leading to increased trans-endothelial uptake into solid 
tumor tissue. Additionally, HA induces receptor-mediated uptake into CD44 
positive HUH7 cells [147], which can only function for the 0.1 equiv. of HA, 
due to the fact it can be determined in relevant levels in tumor tissue, in 
contrast to the anionic formulation. 
The inspection on a histological level specifies the biodistribution studies by 
demonstrating the connection between cationic charge and improved 
tumoral uptake, whereas equiv. of 0.8 HA feature only negligible tumoral 
signal. Interestingly, with time elapsing the intravascular nanoparticle 
concentration reduces, while the portion in surrounding tumor tissue rises. 
While this finding cannot be derived from the previous experiments, it makes 
sense that a time dependent distribution (e.g. after 45 m) is ascertainable. 
Furthermore, the histological examination underlines the hypothesis that 
tumor accumulation of cationic particles is mediated after attachment to 
endothelial cells. 
Also, biochemical determination of important renal and liver parameters and 
regular weight determination indicate biocompatibility and show no signs for 
acute toxicity or dysfunction of liver or kidney after formulation application. 
Further experiments should be performed to investigate the effect in various 
cell lines and for enhanced transporter systems for efficient delivery and 
prolonged blood circulation. Moreover, the relevance of the deployed carrier 
in therapeutic studies should be assessed. 
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V. SUMMARY 
Cancer poses a leading cause for human death worldwide, with numbers 
rising, due to population ageing. Apart from medical causes, economic 
reasons urge for novel treatment approaches. Current treatment options 
lack efficiency, especially for metastasizing non-operable tumors, while 
prophylaxis presents a challenge, because of multifactorial pathogenesis. 
Extensive research in this field, put forth siRNA as an innovative therapeutic 
option with hepatocyte-targeted Patisiran (OnpattroTM) and Givosiran 
(GivlaariTM) being approved for medical application. Still, intratumoral siRNA 
delivery faces multiple obstacles. 
Hence, this thesis aimed at researching hyaluronic acid (HA) shielded and 
targeted sequence-defined oligomeric carriers for specific in vivo delivery of 
siRNA into a subcutaneous human tumor xenograft mouse model after 
intravenous administration. 
In the first part a biodistribution study revealed that only cationic 
formulations managed to reach subcutaneous hepatocellular HUH7 
carcinoma tissue until 1 h after injection, while for the control group and 
higher HA levels, resulting in negatively charged particles, no tumor 
targeting was achieved. A follow up gene silencing study combined cationic 
and anionic formulations with siRNA directed towards the mitosis 
associated EG5 gene. Systemic application lead to a significant target gene 
knockdown of ~80% for cationic particles, comprising 0.1 equiv. of HA, 
whereas anionic nanoparticles did not significantly reduce gene expression 
in subcutaneous HUH7 tumors. For cationic polyplexes subsequent 
histological evaluation evinced efficient binding to endothelial cells in tumor 
vessels followed by transport into surrounding tissue, while only a negligible 
quantity of anionic nanoparticles reached tumoral vessels in the first place. 
Polyplexes modified via click-chemistry with surface shielding and targeting 
ligand HA presented good tolerability after intravenous injection into mice, 
indicated by biochemistry parameters and animal weight being within 
normal range and without significant deviation. 
In sum, a HA-shielded and targeted nanocarrier was demonstrated as an 
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efficient system for siRNA delivery into tumor tissue and subsequent gene 
silencing. These promising results are encouraging regarding further 
studies to develop and enhance siRNA cancer therapeutics. 
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VI. ZUSAMMENFASSUNG 
In vivo Evaluierung polymerischer siRNA Nanoformulierungen für die 
tumorale Genexpressionshemmung 
Weltweit stellt Krebs bei Menschen eine häufige Todesursache mit 
steigenden Fallzahlen aufgrund des zunehmenden Durchschnittsalters dar. 
Neben medizinischen gibt es wirtschaftliche Gründe für neuartige 
Behandlungsansätze. Aktuellen Behandlungsmöglichkeiten fehlt es an 
Wirksamkeit, vor allem bei metastasierenden nicht operablen Tumoren, 
während Vorbeugemaßnahmen, aufgrund der multifaktoriellen 
Krankheitsentstehung, eine Herausforderung darstellen. Umfangreiche 
Forschung auf diesem Gebiet hat siRNA als bahnbrechende 
Therapiemöglichkeit hervorgebracht. Patisiran (OnpattroTM) und Givosiran 
(GivlaariTM), beide für Leber-spezifische RNA Interferenz entwickelt, wurden 
bereits für den medizinischen Einsatz zugelassen. Dennoch muss für den 
Transport von siRNA in Tumorgewebe eine Vielzahl von Hürden 
überwunden werden. 
Daher war es das Ziel dieser Arbeit mit Hyaluronsäure (HA) abgeschirmte 
und ausgerichtete sequenzdefinierte Träger-Oligomere hinsichtlich ihrer 
spezifischen Einschleusung von siRNA in Tumoren nach systemischer 
Verabreichung im Xenograft Mausmodell zu untersuchen. 
Im ersten Teil der Arbeit ergab ein Biodistributionsversuch, dass kationische 
Formulierungen in der Lage waren subkutane hepatozelluläre HUH7 
Tumore für bis eine Stunde zu erreichen, während die Kontrollgruppe bzw. 
höhere HA-Konzentrationen, die negative geladene Teilchen zur Folge 
haben, sich nicht im Tumor anreichern konnten. Im Folgeversuch, der die 
Hemmung der Genexpression untersucht, wurden kationische und 
anionische Formulierungen mit siRNA kombiniert, die sich gegen das an der 
Mitose beteiligte EG5 Gen richtet. Die systemische Gabe der kationischen 
Teilchen, die 0.1 Äquivalente von HA enthalten, führte zu einer signifikanten 
Herunterregulierung des Zielgens von ungefähr 80%, wohingegen die 
anionischen Nanopartikel die Genexpression in subkutanen HUH7-
Tumoren nicht signifikant verminderten. Die nachfolgende histologische 
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Untersuchung zeigte, dass kationische Polyplexe an die Endothelzellen der 
Tumorgefäße binden und danach in das umgebende Tumorgewebe 
transportiert werden, während anionische Formulierungen überhaupt nur in 
vernachlässigbarer Menge den Tumorgefäßen ankommen. 
Die mittels “Klick-Chemie” mit dem abschirmenden Targeting-Ligand HA 
modifizierten Polyplexe zeigen nach intravenöser Injektion in Mäusen gute 
Verträglichkeit. Dies deuten die biochemischen Parameter sowie das 
Tiergewicht an, die innerhalb des Normalbereichs liegen und keinerlei 
signifikante Abweichungen zeigen. 
Summa summarum wurde ein mittels Hyaluronsäure abgeschirmtes und 
zielgerichtetes Trägersystem für den effektiven Transport von siRNA in 
Tumorgewebe mit sich anschließender Genexpressionshemmung etabliert. 
Die vielversprechenden Ergebnisse machen Mut hinsichtlich weiterer 
Studien für die Entwicklung und Verbesserung siRNA-basierter 
Krebstherapeutika. 
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